Webinar
On-Demand Session: Casein kinase 1 alpha degrader DEG-77 targets TP53 WT gynecologic cancers with MDM4 dependence and altered SWI/SNF
Watch the on-demand session.
Learn from Nicole Curnutt, Ph.D. Candidate at Harvard University, presenting: Casein kinase 1 alpha degrader DEG-77 targets TP53 WT gynecologic cancers with MDM4 dependence and altered SWI/SNF.
Presented at Drafts & Discoveries, a scientific exchange co-hosted by EditCo and Promega in Cambridge, MA, this session highlights CK1α as an emerging therapeutic target in oncology and how next-generation degraders like DEG-77 uncover vulnerabilities in TP53 wild-type gynecologic cancers. Nicole discusses how SWI/SNF-deficient ovarian and endometrial cancer models rely on MDM4 to suppress p53 activity, and how CK1α degradation can restore p53 function to trigger apoptosis and cell cycle arrest.